Figure 2
From: Efficacy of an Adenoviral Vectored Multivalent Centralized Influenza Vaccine
Protection Against Lethal H1N1, H3N1 and H3N2 Influenza Virus by Traditional Trivalent Vaccines. Mice were immunized and boosted with the 2010–2011 FDA approved traditional vaccines. The vaccines consisted of either the live-attenuated FluMist or the killed-inactivated FluZone containing influenza A/California/07/2009 X-179A (H1N1)pdm09, A/Victoria/210/2009 X-187 (an A/Perth/16/2009-like virus) (H3N2) and B/Brisbane/60/2008. The mice were immunized using the same vaccine schedule as the Ad vectored vaccines. Sera collected 2 weeks post-boosting was assayed for HI antibody titers against a panel of H1N1, H3N1 and H3N2 influenza viruses (A). Sera from unimmunized control mice were also analyzed for non-specific HI antibody titers. The dotted line represents a theoretical titer indicative of protection (HI titer of 40). The vaccinated mice were challenged with lethal doses of mouse-adapted influenza viruses 4 weeks post-boosting. The mice were monitored for weight loss, disease and survival (B). Mice that lost ≥25% of their baseline weight were humanely euthanized. Weight loss and survival for unvaccinated control groups are shown in Figs 3 and 4.
